ISSN: 1899-0967
Polish Journal of Radiology
Established by prof. Zygmunt Grudziński in 1926 Sun
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
1/2022
vol. 87
 
Share:
Share:
more
 
 
Cardiovascular radiology
abstract:
Original paper

Feature-tracking cardiac magnetic resonance method: a valuable marker of replacement fibrosis in hypertrophic cardiomyopathy

Nahid Rezaeian
1
,
Leila Hosseini
2
,
Negar Omidi
3
,
Mahya Khaki
1
,
Homa Najafi
1
,
Kianoosh Kasani
1
,
Mostafa Mousavizadeh
1
,
Yasaman Khalili
1
,
Mohammad Mehdi Hemmati Komasi
4
,
Yaser Toloueitabar
1
,
Sanaz Asadian
1

1.
Rajaie Cardiovascular Medical and Research Centre, Iran University of Medical Sciences, Tehran, Iran
2.
North Khorasan University of Medical Sciences, Bojnurd, Iran
3.
Tehran Heart Centre (THC), Tehran University of Medical Sciences, Tehran, Iran
4.
Iran University of Medical Sciences, Tehran, Iran
Pol J Radiol 2022; 87: e263-e270
Online publish date: 2022/05/16
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Purpose
Left ventricular (LV) replacement fibrosis is a marker of adverse cardiac events in hypertrophic cardiomyopathy (HCM). We aimed to assess the efficacy of the feature-tracking cardiac magnetic resonance (FT-CMR) in the detection of LV replacement fibrosis.

Material and methods
Fifty-one patients with HCM (51% female, mean age = 21 ± 5.2 years) and significant myocardial hypertrophy, who underwent CMR between February 2018 and December 2019 were enrolled. Functional and 3D FT-CMR parameters were measured. LV global longitudinal strain, global radial strain (GRS), and global circumferential strain (GCS) were recorded. The percentage of enhanced myocardial mass was calculated. Univariate and multivariate regression analyses were performed to determine the predictors of fibrosis. A p-value of less than 0.05 was considered significant.

Results
The mean enhanced mass percentage was 15.2 ± 10.53%. Among LV volumetric parameters, end-systolic and end-diastolic volume indices predicted fibrosis (fitness [F] = 8.11 and p = 0.006 vs. F = 6.6 and p = 0.012, correspondingly). The univariate linear regression demonstrated that GCS and GRS predicted total enhanced mass (%) (F = 12.29 and p = 0.001 vs. F = 7.92 and p = 0.007, respectively). After the inclusion of all volumetric and deformation parameters, the multivariate analysis identified the model of a combination of LV end-diastolic volume index (LV EDVI) and LV GCS as a robust predictor of the fibrosis percentage (F = 8.86 and p = 0.005).

Conclusions
Non-contrast CMR parameters including LV GCS and LV EDVI are valuable markers of replacement fibrosis in HCM patients with notable myocardial hypertrophy.

keywords:

cardiovascular magnetic resonance, feature tracking, hypertrophic cardiomyopathy, late gadolinium enhancement, replacement fibrosis




Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.